Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients
This is a multi-center, open-label study of 2 doses of leuprolide acetate 17 mg depot, administered three months apart, in subjects with prostate cancer who might benefit from medical androgen deprivation therapy
Prostate Cancer
DRUG: leuprolide acetate
Percent of successful patients achieving chemical castration, Days 28, 84, and 168
WHO/ECOG performance status, Days 14, 28, 56, 84, 112, and 168|Serum LH concentration (mIU/mL), Days 2, 14, 28, 56, 84, 86, 112, and 168|Serum FSH concentration (mIU/mL), Days 2, 14, 28, 56, 84, 86, 112, and 168|Serum PSA concentration (ng/mL), Days 2, 14, 28, 56, 84, 86, 112, and 168|Frequency of bone pain, Days 2, 14, 28, 56, 54, 84, 86, 112, and 168|plasma testosterone concentration (ng/mL) in PK population, week 4 and week 12|Occurrence of hot flushes, Days 0, 2, 14, 28, 56, 84, 86, 112, and 168|Plasma leuprolide concentrations (pg/mL) in PK population, Days 2, 14, 28, 56, 84, 86, 112, and 168|Frequency of urinary symptoms, Days 2, 14, 28, 56, 54, 84, 86, 112, and 168|Frequency of urinary pain, Days 2, 14, 28, 56, 54, 84, 86, 112, and 168
This is a multi-center, open-label study of 2 doses of leuprolide acetate 17 mg depot, administered three months apart, in subjects with prostate cancer who might benefit from medical androgen deprivation therapy